Frontiers of Science meets InFLAMES: Janne Lehtiö on air
InFLAMES Visiting Professor Janne Lehtiö will be the speaker in next Frontiers of Science autumn seminar series. The virtual seminar will take place on November 18th .
Professor Lehtiö, who works in Karolinska Institutet, will talk about Cancer molecular phenotyping – Leukemia proteomics defined high risk patient populations in CLL and AML. His host will be Professor Riitta Lahesmaa.
Janne Lehtiö has MSc degree in biochemistry from Helsinki University, Finland and PhD in engineering (biotechnology) at Royal Institute of Technology in Stockholm, Sweden. Post the PhD, Lehtiö worked a few years in biotech industry in USA and Europe; and obtained his postdoctoral experience in cancer research at Karolinska Institutet.
In 2009, Lehtiö got his assistant professor (docent) merit at Karolinska Institutet and obtained the faculty Professor position 2015. Since 2006, Dr. Lehtiö was appointed as director of the Karolinska University Hospital’s clinical proteomics facility.
Currently, Janne Lehtiö is leading a research group of 30 persons at the Department of Oncology-Pathology, KI. He has supervised 15 PhD students and 17 postdoctoral fellows. He has a formal university teacher education and is currently lecturing in four graduate programs at KI and is a frequent lecturer at other Swedish universities and internationally.
Dr Lehtiö’s major research interest is in improving human proteome analysis focusing on precision cancer medicine. Lehtiö has 139 peer reviewed original publication and together with his group, he has published number of novel methods for proteome analysis, multi-omics and cancer research applications in leading journals. The Lehtiö-group’s current proteogenomics research focus is on lung and breast cancer as well as on a newly started program on particular childhood and adult leukemia.
Lehtiö has also vast experience on research infrastructures, from heading core facilities and national infrastructure initiatives to expert assignments in the field of technology driven life science.